137 related articles for article (PubMed ID: 27338302)
21. Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer.
Balli D; Rech AJ; Stanger BZ; Vonderheide RH
Clin Cancer Res; 2017 Jun; 23(12):3129-3138. PubMed ID: 28007776
[No Abstract] [Full Text] [Related]
22. Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer.
Kumai T; Mizukoshi E; Hashiba T; Nakagawa H; Kitahara M; Miyashita T; Mochizuki T; Goto S; Kamigaki T; Takimoto R; Yamashita T; Sakai Y; Yamashita T; Honda M; Tomita K; Kaneko S
Cytotherapy; 2021 Feb; 23(2):137-145. PubMed ID: 32907781
[TBL] [Abstract][Full Text] [Related]
23. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer.
Liu Z; Guo B; Lopez RD
J Gastroenterol Hepatol; 2009 May; 24(5):900-11. PubMed ID: 19175829
[TBL] [Abstract][Full Text] [Related]
24. Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells.
Han L; Shang YM; Song YP; Gao QL
J Immunol Res; 2016; 2016():5706814. PubMed ID: 27433478
[TBL] [Abstract][Full Text] [Related]
25. Tumor-Targeting Salmonella typhimurium A1-R Promotes Tumoricidal CD8
Murakami T; Hiroshima Y; Zhang Y; Zhao M; Kiyuna T; Hwang HK; Miyake K; Homma Y; Mori R; Matsuyama R; Chishima T; Ichikawa Y; Tanaka K; Bouvet M; Endo I; Hoffman RM
J Cell Biochem; 2018 Jan; 119(1):634-639. PubMed ID: 28628234
[TBL] [Abstract][Full Text] [Related]
26. Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients.
Zhang L; Mu Y; Zhang A; Xie J; Chen S; Xu F; Wang W; Zhang Y; Ren S; Zhou C
Oncotarget; 2017 Jul; 8(28):45164-45177. PubMed ID: 28404886
[TBL] [Abstract][Full Text] [Related]
27. Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions.
Amedei A; Niccolai E; Benagiano M; Della Bella C; Cianchi F; Bechi P; Taddei A; Bencini L; Farsi M; Cappello P; Prisco D; Novelli F; D'Elios MM
Cancer Immunol Immunother; 2013 Jul; 62(7):1249-60. PubMed ID: 23640603
[TBL] [Abstract][Full Text] [Related]
28. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice.
Sarkar D; Su ZZ; Vozhilla N; Park ES; Randolph A; Valerie K; Fisher PB
Cancer Res; 2005 Oct; 65(19):9056-63. PubMed ID: 16204080
[TBL] [Abstract][Full Text] [Related]
29. Mathematical model of tumor-immune surveillance.
Mahasa KJ; Ouifki R; Eladdadi A; Pillis L
J Theor Biol; 2016 Sep; 404():312-330. PubMed ID: 27317864
[TBL] [Abstract][Full Text] [Related]
30. Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.
Sanders KL; Fox BA; Bzik DJ
Cancer Immunol Res; 2015 Aug; 3(8):891-901. PubMed ID: 25804437
[TBL] [Abstract][Full Text] [Related]
31. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
[TBL] [Abstract][Full Text] [Related]
32. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
33. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.
Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA
Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121
[TBL] [Abstract][Full Text] [Related]
34. IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.
McMichael EL; Jaime-Ramirez AC; Guenterberg KD; Luedke E; Atwal LS; Campbell AR; Hu Z; Tatum AS; Kondadasula SV; Mo X; Tridandapani S; Bloomston M; Ellison EC; Williams TM; Bekaii-Saab T; Carson WE
Clin Cancer Res; 2017 Jan; 23(2):489-502. PubMed ID: 27435400
[TBL] [Abstract][Full Text] [Related]
35. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells.
Lei J; Wu Z; Jiang Z; Li J; Zong L; Chen X; Duan W; Xu Q; Zhang L; Han L; Ma Q; Wang Z; Zhang D
Oncotarget; 2016 Dec; 7(50):83601-83610. PubMed ID: 27876704
[TBL] [Abstract][Full Text] [Related]
37. The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo.
Silva A; Mount A; Krstevska K; Pejoski D; Hardy MP; Owczarek C; Scotney P; Maraskovsky E; Baz Morelli A
J Immunol; 2015 Mar; 194(5):2199-207. PubMed ID: 25646304
[TBL] [Abstract][Full Text] [Related]
38. Intra-tumoral IFN-γ-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer.
Niccolai E; Taddei A; Ricci F; Rolla S; D'Elios MM; Benagiano M; Bechi P; Bencini L; Ringressi MN; Pini A; Castiglione F; Giordano D; Satolli MA; Coratti A; Cianchi F; Bani D; Prisco D; Novelli F; Amedei A
Clin Sci (Lond); 2016 Feb; 130(4):247-58. PubMed ID: 26590104
[TBL] [Abstract][Full Text] [Related]
39. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
Kubuschok B; Neumann F; Breit R; Sester M; Schormann C; Wagner C; Sester U; Hartmann F; Wagner M; Remberger K; Schilling M; Pfreundschuh M
Clin Cancer Res; 2006 Feb; 12(4):1365-72. PubMed ID: 16489095
[TBL] [Abstract][Full Text] [Related]
40. Enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model.
Castillo-Montiel E; Chimal-Eguía JC; Tello JI; Piñon-Zaráte G; Herrera-Enríquez M; Castell-Rodríguez AE
Theor Biol Med Model; 2015 Jun; 12():11. PubMed ID: 26054860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
